Published in Antimicrob Agents Chemother on February 01, 2005
Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams. Crit Care (2011) 1.48
Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents. Clin Microbiol Rev (2013) 0.99
Protein binding of antimicrobials: methods for quantification and for investigation of its impact on bacterial killing. AAPS J (2009) 0.85
Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis. Antimicrob Agents Chemother (2009) 0.85
Comparison of fluconazole renal penetration levels in healthy and Candida albicans-infected Wistar rats. Antimicrob Agents Chemother (2012) 0.83
Comparable population pharmacokinetics and pharmacodynamic breakpoints of cefpirome in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother (2011) 0.80
Optimizing antimicrobial therapy in critically ill patients. Infect Drug Resist (2014) 0.77
Disposition kinetics and urinary excretion of cefpirome after intravenous injection in buffalo calves. J Vet Sci (2007) 0.75
Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis (1998) 16.20
The ACCP-SCCM consensus conference on sepsis and organ failure. Chest (1992) 4.35
The pharmacodynamics of beta-lactams. Clin Infect Dis (1998) 3.54
The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet (1995) 2.66
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob Agents Chemother (2004) 2.10
Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans. Antimicrob Agents Chemother (1996) 1.83
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother (2004) 1.64
Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med (2001) 1.50
Tissue distribution of imipenem in critically ill patients. Clin Pharmacol Ther (2002) 1.46
Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery. Antimicrob Agents Chemother (1992) 1.45
The reliability of different formulae to predict creatinine clearance. J Intern Med (2003) 1.40
Factors involved in the enhanced efficacy against gram-negative bacteria of fourth generation cephalosporins. J Antimicrob Chemother (1992) 1.38
Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against recent clinical isolates from India: a survey of ten medical center laboratories. Diagn Microbiol Infect Dis (2002) 1.27
Pharmacokinetics and tissue penetration of cefpirome, a new cephalosporin. J Antimicrob Chemother (1988) 1.21
Cefepime versus cefpirome: the importance of creatinine clearance. Anesth Analg (2003) 1.20
Pharmacodynamic effects of subinhibitory antibiotic concentrations. Int J Antimicrob Agents (2001) 1.15
In vitro evaluation of cefepime and other broad-spectrum beta-lactams in 22 medical centers in Japan: a phase II trial comparing two annual organism samples. The Japan Antimicrobial Resistance Study Group. Diagn Microbiol Infect Dis (1999) 1.13
Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis. Crit Care Med (2002) 1.09
Antibiotic susceptibility and mechanisms of beta-lactam resistance in 1310 strains of pseudomonas aeruginosa: a French multicentre study (1996). J Antimicrob Chemother (2000) 1.07
Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis. Antimicrob Agents Chemother (2003) 1.03
A combined in vivo pharmacokinetic-in vitro pharmacodynamic approach to simulate target site pharmacodynamics of antibiotics in humans. J Antimicrob Chemother (2000) 0.99
Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing. Intensive Care Med (2001) 0.95
Closed-chest microdialysis to measure antibiotic penetration into human lung tissue. Am J Respir Crit Care Med (2002) 0.94
In vitro activity of the tricyclic beta-lactam GV104326. Antimicrob Agents Chemother (1996) 0.86
Comparative in-vitro activity of cefpirome against isolates from intensive care and haematology/oncology units. Belgian Multicentre Study Group. J Antimicrob Chemother (1998) 0.85
Target site concentrations after continuous infusion and bolus injection of cefpirome to healthy volunteers. Clin Pharmacol Ther (2000) 0.84
In vitro evaluation of cefepime and other broad-spectrum beta-lactams for isolates in Malaysia and Singapore medical centers. The Malaysia/Singapore Antimicrobial Resistance Study Group. Diagn Microbiol Infect Dis (1999) 0.83
In vitro evaluation of cefepime and other broad-spectrum beta-lactams in Taiwan medical centers. The Taiwan Antimicrobial Resistance Study Group. Diagn Microbiol Infect Dis (1999) 0.78
Micellar electrokinetic chromatography for the analysis of cefpirome in microdialysis and plasma samples obtained in vivo from human volunteers. Electrophoresis (2000) 0.78
pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics (2011) 16.75
Tissue distribution of 5-hydroxymethylcytosine and search for active demethylation intermediates. PLoS One (2010) 6.38
The discovery of 5-formylcytosine in embryonic stem cell DNA. Angew Chem Int Ed Engl (2011) 4.39
Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized derivatives. Cell (2013) 4.16
SuperHirn - a novel tool for high resolution LC-MS-based peptide/protein profiling. Proteomics (2007) 3.60
Quantification of the sixth DNA base hydroxymethylcytosine in the brain. Angew Chem Int Ed Engl (2010) 3.50
Safety and immunogenicity of a novel multivalent OspA vaccine against Lyme borreliosis in healthy adults: a double-blind, randomised, dose-escalation phase 1/2 trial. Lancet Infect Dis (2013) 3.46
A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med (2008) 3.28
An integrated mass spectrometric and computational framework for the analysis of protein interaction networks. Nat Biotechnol (2007) 2.59
Internal mammary artery harvesting influences antibiotic penetration into presternal tissue. Ann Thorac Surg (2013) 2.14
Effects of carbon monoxide inhalation during experimental endotoxemia in humans. Am J Respir Crit Care Med (2004) 1.98
Impaired circadian rhythm of melatonin secretion in sedated critically ill patients with severe sepsis. Crit Care Med (2002) 1.96
C-reactive protein and all-cause mortality in a large hospital-based cohort. Clin Chem (2007) 1.79
Multi-hit inhibition of circulating and cell-associated components of the toll-like receptor 4 pathway by oxidized phospholipids. Arterioscler Thromb Vasc Biol (2008) 1.76
High resolution PTR-TOF: quantification and formula confirmation of VOC in real time. J Am Soc Mass Spectrom (2010) 1.72
Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection. J Urol (2008) 1.68
Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med (2005) 1.67
In vitro and in vivo evaluation of [18F]ciprofloxacin for the imaging of bacterial infections with PET. Eur J Nucl Med Mol Imaging (2004) 1.67
Bioinformatics for protein biomarker panel classification: what is needed to bring biomarker panels into in vitro diagnostics? Expert Rev Proteomics (2009) 1.61
Plasma concentrations of interleukin-6, organ failure, vasopressor support, and successful coronary revascularization in predicting 30-day mortality of patients with cardiogenic shock complicating acute myocardial infarction. Crit Care Med (2006) 1.58
Gamma glutamyltransferase and long-term survival: is it just the liver? Clin Chem (2007) 1.56
A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET. J Nucl Med (2009) 1.56
Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil. Epilepsia (2007) 1.55
The EGF A61G polymorphism is associated with disease-free period and survival in malignant melanoma. J Invest Dermatol (2006) 1.52
Inflammation-induced vasoconstrictor hyporeactivity is caused by oxidative stress. J Am Coll Cardiol (2003) 1.51
Cerebrospinal fluid impairs antimicrobial activity of fosfomycin in vitro. J Antimicrob Chemother (2009) 1.49
Cost-effectiveness of preoperative SPECT/CT combined with lymphoscintigraphy vs. lymphoscintigraphy for sentinel lymph node excision in patients with cutaneous malignant melanoma. Eur J Nucl Med Mol Imaging (2014) 1.49
An open-system quantum simulator with trapped ions. Nature (2011) 1.46
In vivo profile of the human leukocyte microRNA response to endotoxemia. Biochem Biophys Res Commun (2009) 1.45
Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med (2003) 1.44
Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET. J Nucl Med (2008) 1.44
Bactericidal effect of different laser systems in the deep layers of dentin. Lasers Surg Med (2004) 1.43
Processing and classification of protein mass spectra. Mass Spectrom Rev (2006) 1.42
Search strategies-identified reports on "off-label" drug use in MEDLINE. J Clin Epidemiol (2012) 1.41
Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. J Clin Oncol (2012) 1.41
The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Pharmacology (2006) 1.40
Automated protein identification by tandem mass spectrometry: issues and strategies. Mass Spectrom Rev (2006) 1.40
Quantitative proteomic analysis of protein complexes: concurrent identification of interactors and their state of phosphorylation. Mol Cell Proteomics (2007) 1.38
Clinical applications of levofloxacin for severe infections. Chemotherapy (2004) 1.38
AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res (2007) 1.35
Mechanism and stem-cell activity of 5-carboxycytosine decarboxylation determined by isotope tracing. Angew Chem Int Ed Engl (2012) 1.34
Blood-brain barrier P-glycoprotein function in Alzheimer's disease. Brain (2011) 1.33
Mean platelet volume may represent a predictive parameter for overall vascular mortality and ischemic heart disease. Arterioscler Thromb Vasc Biol (2011) 1.31
Principles of antibiotic penetration into abscess fluid. Pharmacology (2006) 1.30
Low values of 5-hydroxymethylcytosine (5hmC), the "sixth base," are associated with anaplasia in human brain tumors. Int J Cancer (2012) 1.30
Dissociable network properties of anesthetic state transitions. Anesthesiology (2011) 1.29
Peripheral metabolism of (R)-[11C]verapamil in epilepsy patients. Eur J Nucl Med Mol Imaging (2007) 1.25
Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica (2012) 1.25
Quantum Google in a complex network. Sci Rep (2013) 1.24
Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int J Antimicrob Agents (2002) 1.23
Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET. Eur J Nucl Med Mol Imaging (2009) 1.23
Antibiotic abscess penetration: fosfomycin levels measured in pus and simulated concentration-time profiles. Antimicrob Agents Chemother (2005) 1.22
The high-affinity binding site for tricyclic antidepressants resides in the outer vestibule of the serotonin transporter. Mol Pharmacol (2010) 1.21
A combined CXCL10, CXCL8 and H-FABP panel for the staging of human African trypanosomiasis patients. PLoS Negl Trop Dis (2009) 1.20
Synthesis and in vivo evaluation of [11C]tariquidar, a positron emission tomography radiotracer based on a third-generation P-glycoprotein inhibitor. Bioorg Med Chem (2010) 1.20
EasyProt--an easy-to-use graphical platform for proteomics data analysis. J Proteomics (2012) 1.20
Simvastatin prevents vascular hyporeactivity during inflammation. Circulation (2004) 1.20
Influence of functional haplotypes in the drug transporter gene ABCB1 on central nervous system drug distribution in humans. Clin Pharmacol Ther (2005) 1.19
Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol (2006) 1.18
Effect of interleukin-6 blockade on tissue factor-induced coagulation in human endotoxemia. Crit Care Med (2004) 1.18
Mutation in the Scyl1 gene encoding amino-terminal kinase-like protein causes a recessive form of spinocerebellar neurodegeneration. EMBO Rep (2007) 1.18
Detection of plant volatiles after leaf wounding and darkening by proton transfer reaction "time-of-flight" mass spectrometry (PTR-TOF). PLoS One (2011) 1.15
Daptomycin: a review 4 years after first approval. Pharmacology (2007) 1.15
Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J Antimicrob Chemother (2010) 1.15
High fosfomycin concentrations in bone and peripheral soft tissue in diabetic patients presenting with bacterial foot infection. J Antimicrob Chemother (2009) 1.14
Parallel isotope-based quantification of modified tRNA nucleosides. Angew Chem Int Ed Engl (2009) 1.14
pH dependence of melanoma cell migration: protons extruded by NHE1 dominate protons of the bulk solution. J Physiol (2007) 1.13
Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients. AIDS (2012) 1.12
Citrate kinetics in patients receiving long-term hemodialysis therapy. Am J Kidney Dis (2005) 1.12
Role for staphylococci in misguided thrombus resolution of chronic thromboembolic pulmonary hypertension. Arterioscler Thromb Vasc Biol (2008) 1.11
Microdialysis: current applications in clinical pharmacokinetic studies and its potential role in the future. Clin Pharmacokinet (2005) 1.10
A cell culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J Infect Dis (2009) 1.10
Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses. Antimicrob Agents Chemother (2005) 1.10
Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis. Crit Care Med (2002) 1.09
Synthesis and small-animal positron emission tomography evaluation of [11C]-elacridar as a radiotracer to assess the distribution of P-glycoprotein at the blood-brain barrier. J Med Chem (2009) 1.09
Reversible bond formation enables the replication and amplification of a crosslinking salen complex as an orthogonal base pair. Nat Chem (2011) 1.07
On-line breath analysis with PTR-TOF. J Breath Res (2009) 1.06
Limitations of small animal PET imaging with [18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease. Mol Imaging Biol (2009) 1.06
Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake. Clin Cancer Res (2011) 1.06
Cardiogenic shock due to myocardial infarction: diagnosis, monitoring and treatment: a German-Austrian S3 Guideline. Dtsch Arztebl Int (2012) 1.06
Tumor necrosis factor-alpha inhibits renin gene expression. Am J Physiol Regul Integr Comp Physiol (2002) 1.05
Alternative pathway for atmospheric particles growth. Proc Natl Acad Sci U S A (2012) 1.02
Polyphenylene Nanostructures. Chem Rev (1999) 1.02
A novel positron emission tomography imaging protocol identifies seizure-induced regional overactivity of P-glycoprotein at the blood-brain barrier. J Neurosci (2011) 1.02
Multiple organ failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6. Crit Care Med (2002) 1.02
Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis--a pharmacokinetic study. Nephrol Dial Transplant (2009) 1.02
Exercise training lowers plasma visfatin concentrations in patients with type 1 diabetes. J Clin Endocrinol Metab (2006) 1.02